Janssen Vaccines

Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO

Retrieved on: 
Tuesday, August 29, 2023
Biotechnology, Pharmaceutical, Health, SPAC, IPO, Analytical chemistry, Therapy, University, Doctor of Philosophy, Takeda, CSO, Phase II, Erasmus University Rotterdam, Business, MBA, Business administration, EQT, Fellow of the Academy of Medical Sciences, Acquisition, INSEAD, Hidradenitis suppurativa, Janssen Vaccines, Immune-mediated inflammatory diseases, Sanofi, In Ictu Oculi, Johnson & Johnson, TiGenix, Commercial, GSK plc, Rheumatoid arthritis, Janssen Pharmaceuticals, Management, Citryl-CoA lyase

Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo Bravo as Chief Executive Officer.

Key Points: 
  • Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo Bravo as Chief Executive Officer.
  • In addition, Citryll has appointed Tim Schenk, Ph.D., as Chief Business Officer.
  • Dr. Schenk brings with him a broad background in business and commercial development across the life sciences industry.
  • As Mr. Bravo steps into the CEO role, Eric Meldrum, Ph.D., will fully resume his position as Chief Scientific Officer at Citryll.

Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors

Retrieved on: 
Thursday, July 20, 2023
Health, Biotechnology, Business development, Quality of life (healthcare), Therapy, MB, Invitrogen, Business, University College Dublin, Immunology, RNA, Antibody, Doctor of Philosophy, MD, Janssen Vaccines, Drug discovery, Knowledge, Neurology, Leiden University, Pharmaceutical industry, Management, Galápagos Islands, Medicine

Sapreme , a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors.

Key Points: 
  • Sapreme , a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors.
  • “We value the breadth and depth of Andre’s and Jeanne’s expertise and track record as Sapreme continues to grow and deliver on the potential of our technology.
  • She currently sits on the board of Life Healthcare SA and is Chairperson of the board at ExeVir and at Astrivax.
  • Dr. Hoekema currently serves as board member of biotech companies Artax Biopharma, Fibrocor Therapeutics and Mimetas B.V.

Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company's Board of Directors

Retrieved on: 
Tuesday, March 7, 2023
Cytokine, Invitrogen, Genentech, Research, Business development, Autoimmune disease, Janssen Vaccines, Autoimmunity, Therapy, Leiden University, Patient, Mergers and acquisitions, Compugen (company), Intellectual property, Collaboration, Immunosuppression, Pharmaceutical industry, Medical device, Management

CAMBRIDGE, Mass., March 7, 2023 /PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company has appointed Andre Hoekema, Ph.D., to the Company's Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., March 7, 2023 /PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company has appointed Andre Hoekema, Ph.D., to the Company's Board of Directors.
  • Dr. Hoekema joins the Artax Biopharma Board of Directors as the Company is evaluating AX-158 in clinical trials.
  • Dr. Hoekema joins the Artax Biopharma Board of Directors as the Company is currently evaluating AX-158 in clinical trials.
  • He also serves as a supervisory board member of early-stage biotech companies Fibrocor Therapeutics, located in Canada, and Mimetas B.V. and Sapreme Technologies B.V., both headquartered in Holland.

Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair

Retrieved on: 
Tuesday, December 20, 2022
Antibody, Immunotherapy, Patient, Inflammation, Janssen Vaccines, Utrecht University, Chair, Therapy, HUB, Columbia University, Vaccine, Doctor of Philosophy, Cancer, Pharmaceutical industry, Meru University of Science and Technology, Entrepreneurship

CAMBRIDGE, England, Dec. 20, 2022 /PRNewswire/ --  Mestag Therapeutics ("Mestag"), an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory disease, today announced the appointment of Prof.

Key Points: 
  • CAMBRIDGE, England, Dec. 20, 2022 /PRNewswire/ --  Mestag Therapeutics ("Mestag"), an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory disease, today announced the appointment of Prof.
  • Ton Logtenberg as Chair.
  • "Ton has provided invaluable guidance as we move our lead programs through discovery phase and ever closer towards the clinic," said Susan Hill, PhD, Chief Executive Officer of Mestag Therapeutics.
  • Ton Logtenberg joined the Board of Mestag Therapeutics in early 2022.

ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates

Retrieved on: 
Wednesday, June 1, 2022
Axiom Space, Company, Adenosine deaminase, Doctor of Philosophy, COVID-19, Supervisory board, University of Nijmegen (1655–80), U.S. Securities and Exchange Commission, Alnylam Pharmaceuticals, Intellectual property, Cancer, Forward-looking statement, CEO, MyTomorrows, Mass meeting, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, General counsel, Corporation, University, RNA, Security (finance), ProQR, Shareholder, Patient, Chief financial officer, Lawyer, GE Capital, AGM, Lists of diseases, Janssen Vaccines, Mutation, Leadership, Research, Annual report, Nasdaq, Therapy, GLOBE, ADAR, Risk, Corporate development, De Boer, Safety, Management, Pharmaceutical industry, Renewable energy

ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.

Key Points: 
  • ProQR has appointed Ren Beukema as a member of the management team in the role of Chief Corporate Development Officer and General Counsel.
  • Mr. Beukema is also nominated to join the Management Board, subject to approval by shareholders at the AGM.
  • Most recently, he has been General Counsel & Chief Corporate Development at Frame Cancer Therapeutics.
  • He is the scientific co-founder of ProQR and previously served as ProQRs Chief Innovation Officer from 2014 to 2022.

Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism

Retrieved on: 
Thursday, April 21, 2022
CEO, Congenital hyperinsulinism, Science, GLOBE, Janssen Vaccines, Death, Patient, Alnylam Pharmaceuticals, CSO, Insulin, Hypoglycemia, Seizure, CMO, Â, Industry, Disease, Prosensa, Coma, CHI, Quality of life, Knowledge, Therapy, Pharmaceutical industry, Galápagos Islands

AMSTERDAM, April 21, 2022 (GLOBE NEWSWIRE) -- Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces today the completion of a seed funding round.

Key Points: 
  • AMSTERDAM, April 21, 2022 (GLOBE NEWSWIRE) -- Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces today the completion of a seed funding round.
  • Xinvento was founded in 2021 by CEO Claudine van der Sande, the driving force behind the company, who has a son diagnosed with Congenital Hyperinsulinism (CHI).
  • This rare disease is characterized by hypoglycemia (hypos) resulting from an over-secretion of insulin.
  • By developing an effective treatment our focus is to improve the quality of life of CHI patients and their families.

Galapagos appoints Paul Stoffels as Chief Executive Officer

Retrieved on: 
Wednesday, January 26, 2022
Tropical medicine, Diepenbeek, Institute, University of Antwerp, Gilead, Infection, COVID-19, Janssen Vaccines, J&J, Research, Medicine, Bernhard Nocht Institute for Tropical Medicine, University, S-1 Executive Committee, Leadership, Inflammation, NASDAQ, Executive Committee, Industry, Galapagos NV, CET, Patient, Fibrosis, Euronext, Retirement, Acquisition, CEO, Management, Fine chemical, Pharmaceutical industry, Virco, Tibotec, Galápagos Islands

Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement

Key Points: 
  • Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement
    Recognized as inspirational industry leader with exceptional R&D as well as global executive experience, and a strong focus on bringing innovative medicines to patients
    Mechelen, Belgium; 26 January 2022, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) is pleased to announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022.
  • After a rigorous selection process, we are very pleased to announce Paul as our next CEO.
  • Given his extraordinary R&D as well as managerial experience, extensive network, along with his deep understanding of Galapagos strengths and potential, we are convinced that Paul is uniquely qualified to lead Galapagos, said Dr. Raj Parekh, Chairman of Galapagos.
  • After a transition period during which Onno will hand over his activities, Paul Stoffels* will fully take over as CEO effective April 1, 2022.

Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses

Retrieved on: 
Tuesday, January 25, 2022
Janssen Pharmaceuticals, Byers, BD, Supervisory board, Infection, PanFlu, VIR, MIT, Coronavirus, COVID-19, Janssen Vaccines, Virus, Board, SoftBank Group, Research, Pandemic, Technology, Capital, Labs, Nose, Genentech, 2009 Davis Cup, CCO, Harvard University, Company, Degenerative disease, Freedom, Influenza, Business development, CSO, GV (company), Influenza and Other Respiratory Viruses, GLOBE, CBO, CEO, General partnership, Vaccine, Management, GV, Chiron

AMSTERDAM and BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Leyden Laboratories B.V., (the "Company" or "Leyden Labs") today announced closing a $140M Series B financing, bringing its total capital raised to approximately $200M in 2021. Series A investors Casdin Capital and GV (formerly Google Ventures) led the round that included incoming investors SoftBank Vision Fund 2, Invus, and Bluebird Ventures, and existing Series A investors F-Prime Capital and Byers Capital/Brook Byers. This international syndicate will support Leyden Labs’ mission to free people from the burden of respiratory viruses. The Board will expand to include Eli Casdin of Casdin Capital as a new member. Vali Barsan of Softbank Investment Advisers, Jeff Bird of Bluebird Ventures, and Suzanne Jung Angell of Casdin Capital join the Board as observers.

Key Points: 
  • This international syndicate will support Leyden Labs mission to free people from the burden of respiratory viruses.
  • The proceeds from the financing will support the development of Leyden Labs platform, product portfolio, and team.
  • Leyden Labs platform is built on two innovative concepts: broad protection against known viruses, new variants and newly emerging viruses, and protection at the gate, in the mucosa (e.g.
  • This fundraising underscores our investors belief that Leyden Labs platform can generate cornerstone products to combat respiratory diseases.

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Retrieved on: 
Wednesday, August 25, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Industry, HF, Cardiomyopathy, Neurodegeneration, Degenerative disease, Janssen Vaccines, Venture round, Fibrosis, RNA transfection, Therapy, Growth, Technology, Hypertrophy, Series, RNA, Death, Bristol Myers Squibb, Heart, Board, Safety, Patient, Organization, SPAC, LSP, Heart failure, Medication, Pharmaceutical industry, Medical device, CDR132L, Cardior, INKEF Capital, LSP, CDR132L, CARDIOR, INKEF CAPITAL, LSP

Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a 64 million ($76 million) Series B financing round.

Key Points: 
  • Cardior Pharmaceuticals , a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, announced today the closing of a 64 million ($76 million) Series B financing round.
  • We believe ncRNAs can fundamentally change the treatment of heart disease by preventing, repairing and reversing damage to cardiac tissue.
  • This substantial funding, provided by leading biotech investors, validates the strength of our RNA approach and our team.
  • The Series B proceeds will be used to fund the late-stage clinical development of Cardiors lead program and the expansion of the companys earlier-stage pipeline.

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial

Retrieved on: 
Thursday, June 10, 2021
Health sciences, Health care, Life sciences, Vaccination, Madison, New Jersey, Pfizer, Wyeth, Pneumococcal conjugate vaccine, Pharmaceutical industry, Vaccine, Janssen Vaccines

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial.

Key Points: 
  • MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial.
  • Michael Shine is a pharmaceutical and biotechnology executive with nearly 35 years of industry experience.
  • Shine has held leadership positions within large pharmaceutical companies, including Novapharm Therapeutics, Colgate Oral Pharmaceutical, and Pfizer Vaccines (formerly Wyeth).
  • Shine led the successful commercial launch of the global $6 billion Prevnar vaccine franchise while with Pfizer Vaccines (formerly Wyeth).